Posted on January 4, 2019 by Sitemaster
Not so long ago, one of the new immunotherapeutic agents (a PD-1 inhibitor called pembrolizumab or Keytruda) was approved by the US Food and Drug Administration (FDA) for the treatment of so-called microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors — regardless of the biological site of origin of those tumors. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: dMMR, genotype, Management, MSI-H, phenotype, prevalence, rare, risk | 1 Comment »
Posted on October 11, 2012 by Sitemaster
The vast majority of prostate cancers are adenocarcinomas of the prostate, i.e., cancers that start in the epithelial cells of the prostate gland. Most of these adenocarcinomas have a well-defined, “normal” cancer histology. However, there are five categories of rare adenocarcinoma, with differing levels of risk. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: adenocarcinoma, incidence, mortality, rare, subtype | Leave a comment »
Posted on February 4, 2011 by Sitemaster
February 28, 2011 is Rare Disease Day — here in America and around the world. Sponsored by EURORDIS and by other national rare disease organizations (including the National Organization of Rare Disorders here in the USA), Rare Disease Day is held on the last day of February every year. … READ MORE …
Filed under: Diagnosis, Risk, Uncategorized | Tagged: rare | Leave a comment »
Posted on January 13, 2011 by Sitemaster
“Signet ring cell” cancer of the prostate is a very rare and usually aggressive form of prostate cancer. It can occur in primary and secondary forms. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: adenocarcinoma, rare, signet ring cell, vesical | Leave a comment »
Posted on November 5, 2008 by Sitemaster
Mazzucchelli et al. have just published a sound and straightforward review discussing the rarer forms of prostate cancer, such as small cell carcinoma of the prostate, ductal adenocarcinoma, basal cell carcinoma of the prostate, and others. The entire paper is available on line and will be a useful resource for support group leaders, mentors, and others who help to inform, educate and support newly diagnosed patients.
Filed under: Diagnosis, Management, Treatment | Tagged: rare | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 